David Amsellem
Stock Analyst at Piper Sandler
(4.86)
# 371
Out of 5,023 analysts
873
Total ratings
59.9%
Success rate
15.2%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BIIB Biogen | Reiterated: Buy | $245 | $219.88 | +11.42% | 33 | Oct 5, 2026 | |
| AMGN Amgen | Reiterated: Buy | $457 | $403.04 | +13.39% | 55 | Oct 5, 2026 | |
| TLV: TEVA Teva Pharmaceutical Industries Limited | Reiterated: Buy | ILA 13,430 | ILA 12,160 | +10.45% | 1 | Oct 1, 2026 | |
| NBIX Neurocrine Biosciences | Reiterated: Buy | $210 | $143.18 | +46.67% | 44 | Oct 1, 2026 | |
| JAZZ Jazz Pharmaceuticals | Reiterated: Buy | $310 | $235.67 | +31.54% | 71 | Sep 28, 2026 | |
| ABBV AbbVie | Reiterated: Buy | $303 | $262.82 | +15.29% | 27 | Sep 23, 2026 | |
| AXSM Axsome Therapeutics | Reiterated: Buy | $258 | $179.25 | +43.93% | 28 | Sep 18, 2026 | |
| BMY Bristol-Myers Squibb Company | Reiterated: Buy | $75 → $82 | $61.15 | +34.10% | 19 | Sep 16, 2026 | |
| VTRS Viatris | Reiterated: Hold | $12 → $13 | $17.60 | -26.14% | 25 | Sep 16, 2026 | |
| XERS Xeris Biopharma Holdings | Reiterated: Hold | $8 | $9.08 | -11.89% | 15 | Sep 10, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $165 | $116.23 | +41.96% | 34 | Aug 21, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $37.40 | +100.53% | 7 | Aug 17, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 | $20.60 | +133.01% | 4 | Aug 14, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $21 → $20 | $25.43 | -21.35% | 41 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $44 → $43 | $22.02 | +95.28% | 46 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $65 | $41.75 | +55.69% | 42 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $66 | $42.38 | +55.73% | 70 | Jul 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $17 | $20.30 | -16.26% | 42 | Jul 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $54 → $59 | $35.71 | +65.22% | 14 | May 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $8 | $4.55 | +75.82% | 7 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $18 | $10.20 | +76.47% | 6 | May 15, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | $5 → $14 | $13.72 | +2.04% | 18 | Apr 28, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $94 → $111 | $72.18 | +53.78% | 4 | Apr 23, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $48 → $46 | $39.64 | +16.04% | 17 | Apr 22, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $15 → $9 | $9.60 | n/a | 19 | Mar 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $11 → $12 | $25.21 | n/a | 39 | Nov 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Sell | $4.24 | $8.27 | n/a | 64 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $21 → $18 | $3.64 | n/a | 9 | May 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 → $12 | $1.15 | n/a | 12 | May 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Sell | $26 → $17 | $0.97 | n/a | 29 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2 | $0.0078 | n/a | 7 | May 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $20 → $3 | $22.27 | n/a | 5 | Nov 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $6 → $175 | $0.000001 | n/a | 7 | May 6, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Hold | n/a | $27.80 | n/a | 1 | Jan 23, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $3 → $2 | $1.13 | n/a | 10 | Oct 12, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $6 | $0.0003 | n/a | 1 | Nov 11, 2013 |
Biogen
Oct 5, 2026
Reiterated: Buy
Price Target: $245
Current: $219.88
Upside: +11.42%
Amgen
Oct 5, 2026
Reiterated: Buy
Price Target: $457
Current: $403.04
Upside: +13.39%
Teva Pharmaceutical Industries Limited
Oct 1, 2026
Reiterated: Buy
Price Target: ILA 13,430
Current: ILA 12,160
Upside: +10.45%
Neurocrine Biosciences
Oct 1, 2026
Reiterated: Buy
Price Target: $210
Current: $143.18
Upside: +46.67%
Jazz Pharmaceuticals
Sep 28, 2026
Reiterated: Buy
Price Target: $310
Current: $235.67
Upside: +31.54%
AbbVie
Sep 23, 2026
Reiterated: Buy
Price Target: $303
Current: $262.82
Upside: +15.29%
Axsome Therapeutics
Sep 18, 2026
Reiterated: Buy
Price Target: $258
Current: $179.25
Upside: +43.93%
Bristol-Myers Squibb Company
Sep 16, 2026
Reiterated: Buy
Price Target: $75 → $82
Current: $61.15
Upside: +34.10%
Viatris
Sep 16, 2026
Reiterated: Hold
Price Target: $12 → $13
Current: $17.60
Upside: -26.14%
Xeris Biopharma Holdings
Sep 10, 2026
Reiterated: Hold
Price Target: $8
Current: $9.08
Upside: -11.89%
Aug 21, 2026
Reiterated: Buy
Price Target: $165
Current: $116.23
Upside: +41.96%
Aug 17, 2026
Reiterated: Buy
Price Target: $75
Current: $37.40
Upside: +100.53%
Aug 14, 2026
Reiterated: Buy
Price Target: $48
Current: $20.60
Upside: +133.01%
Aug 7, 2026
Reiterated: Hold
Price Target: $21 → $20
Current: $25.43
Upside: -21.35%
Aug 7, 2026
Reiterated: Hold
Price Target: $44 → $43
Current: $22.02
Upside: +95.28%
Aug 6, 2026
Reiterated: Buy
Price Target: $65
Current: $41.75
Upside: +55.69%
Jul 27, 2026
Reiterated: Buy
Price Target: $66
Current: $42.38
Upside: +55.73%
Jul 20, 2026
Reiterated: Buy
Price Target: $17
Current: $20.30
Upside: -16.26%
May 22, 2026
Reiterated: Buy
Price Target: $54 → $59
Current: $35.71
Upside: +65.22%
May 15, 2026
Reiterated: Buy
Price Target: $8
Current: $4.55
Upside: +75.82%
May 15, 2026
Reiterated: Buy
Price Target: $18
Current: $10.20
Upside: +76.47%
Apr 28, 2026
Upgraded: Hold
Price Target: $5 → $14
Current: $13.72
Upside: +2.04%
Apr 23, 2026
Reiterated: Buy
Price Target: $94 → $111
Current: $72.18
Upside: +53.78%
Apr 22, 2026
Reiterated: Buy
Price Target: $48 → $46
Current: $39.64
Upside: +16.04%
Mar 21, 2025
Downgraded: Hold
Price Target: $15 → $9
Current: $9.60
Upside: n/a
Nov 7, 2024
Reiterated: Hold
Price Target: $11 → $12
Current: $25.21
Upside: n/a
Oct 31, 2024
Reiterated: Sell
Price Target: $4.24
Current: $8.27
Upside: n/a
May 22, 2024
Reiterated: Buy
Price Target: $21 → $18
Current: $3.64
Upside: n/a
May 14, 2024
Reiterated: Hold
Price Target: $1 → $12
Current: $1.15
Upside: n/a
Aug 9, 2023
Downgraded: Sell
Price Target: $26 → $17
Current: $0.97
Upside: n/a
May 25, 2022
Reiterated: Buy
Price Target: $2
Current: $0.0078
Upside: n/a
Nov 10, 2021
Reiterated: Buy
Price Target: $20 → $3
Current: $22.27
Upside: n/a
May 6, 2021
Reiterated: Buy
Price Target: $6 → $175
Current: $0.000001
Upside: n/a
Jan 23, 2019
Upgraded: Hold
Price Target: n/a
Current: $27.80
Upside: n/a
Oct 12, 2017
Reiterated: Hold
Price Target: $3 → $2
Current: $1.13
Upside: n/a
Nov 11, 2013
Initiated Coverage: Buy
Price Target: $6
Current: $0.0003
Upside: n/a